Shukra Pharmaceuticals
- Market cap
- ₹ 2,827 Cr.
- P/E
- 93.6x
- P/B
- 30.48x
- 52-week range
- 40.06 – 76.5
- ROE
- 29%
- ROCE
- 37%
- Dividend yield
- 0%
- Debt / equity
- 0.06
- Sector
- Pharmaceuticals & Biotechnology
- Industry
- Pharmaceuticals
- Listed on
- NSE, BSE
About
Shukra Pharmaceuticals Limited is an India-based pharmaceutical company engaged in developing, manufacturing and marketing a range of pharmaceutical products globally and domestically. The Company’s product portfolio consists of tablet and capsules (general) solid oral dosage form and small volume parenteral- liquid injection vial and ampules. The Company’s products include Losartan Potassium Tablets USP 50 mg, Glimepiride Tablets USP 2 mg, Pantoprazole Tablets USP 40 mg, Methocarbamol Tablets USP 500 mg, Omeprazole Capsule IP 20 mg, Amlodipine besylate Tablets USP 5 mg, Ranitidine Tablets USP 150 mg, Ranitidine Tablets USP 300 mg, Ciprofloxacin Tablets USP 250 mg, Ciprofloxacin Tablets USP 500 mg, Atorvastatin Tablets USP 10mg, Sildenafil citrate Tablets BP 100 mg, Diclofenac Sodium Tablets BP 50 mg, Mebendazole Tablets USP 100 mg, Paracetamol Tablets BP 500 mg, Artemether 80 mg and Lumefantrine 480 mg Tablets, Clotrimazole Vaginal Tablets 100 mg and others.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Pharmaceuticals: 221 companies →Shukra Pharmaceuticals against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)93.6 against a typical 34.3: pricier than most peers (1st = cheapest).190th of 220
- Sales growth+380% against a typical +15.6% from a year earlier.5th of 197
- Profit growth+1,400% against a typical +18.9% from a year earlier.3rd of 160
- Size₹ 2,826.8 Cr. market value against a typical ₹ 507.7 Cr. (1st = largest).65th of 199
Latest announcements
Exchange filings and their impact on the company.
- Promoters converted final 17.35 lakh warrants at Rs 35.56, paying Rs 4.63 cr and lifting stake to 20%.
Shukra Pharmaceuticals allotted 17.35 lakh equity shares of Re 1 each to promoters Ms. Anar Jayesh Patel and Anar Projects Private Limited on conversion of warrants at Rs 35.56 per share. The company received Rs 4.63 crore as the balance 75% payment. After this, all 46.43 lakh warrants issued in January 2026 are converted, promoter holding rises to 20.01% and paid-up capital rises to 44.25 crore shares.
Fund raises
QIPs, preferential issues, warrants and rights issues, one row per filing, newest first. Open a row for details. All fund raise updates
| Stage | Details | |||||
|---|---|---|---|---|---|---|
| 6 Oct 2026 | Warrant conversion | Allotted | ₹ 4.63 Cr. | ₹ 35.56 | +102.36% |
Board meetings
Results dates and other board meetings. Full calendar
| Details | ||
|---|---|---|
| 3 Nov 2026Upcoming | Financial Results | To consider and approve the financial results for the period ended September 30, 2026 |
| 4 Nov 2026Upcoming | Financial Results | SHUKRAPHAR : 04-Nov-2026 : The Company has informed the Exchange that a Board meeting to be held on November 03, 2026 has been re-scheduled. Further, the Company has informed the Exchange that the meeting of the Board of Directors of the Company will be held on November 04, 2026, To consider and approve the financial results for the period ended September 30, 2026 |
| 22 Aug 2026 | Other business matters | To consider other business matters |
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 25 | 19 | 11 | 3 | 6 | 11 | 13 | 5 | 6 | 39 | 6 | 24 |
| Expenses | 20 | 9 | 6 | 2 | 5 | 7 | 6 | 4 | 6 | 12 | 6 | 2 |
| Operating Profit | 5 | 10 | 4 | 1 | 1 | 4 | 7 | 1 | 0 | 27 | 1 | 21 |
| OPM % | 21% | 51% | 41% | 25% | 12% | 37% | 55% | 24% | −7% | 69% | 11% | 90% |
| Other Income | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Profit before tax | 5 | 10 | 5 | 1 | 1 | 4 | 8 | 1 | 0 | 27 | 0 | 20 |
| Tax % | 0% | 1% | 24% | 41% | 39% | 23% | 29% | 26% | −1,090% | 24% | 568% | 26% |
| Net Profit | 5 | 9 | 4 | 0 | 1 | 3 | 5 | 1 | 2 | 20 | −2 | 15 |
| EPS in Rs | 0.11 | 0.22 | 0.09 | 0.01 | 0.01 | 0.07 | 0.12 | 0.02 | 0.05 | 0.46 | −0.04 | 0.34 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- 28%
- 5 Years
- 38%
- 3 Years
- −1%
- TTM
- 115%
- 10 Years
- 53%
- 5 Years
- 175%
- 3 Years
- 71%
- TTM
- 256%
- 10 Years
- 66%
- 5 Years
- 168%
- 3 Years
- 145%
- TTM
- —
- 10 Years
- 20%
- 5 Years
- 26%
- 3 Years
- 28%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Shukra Pharmaceuticals | ₹ 71.96 | ₹ 2,827 Cr. | 93.6x | 30.5x | 29% | — |
| Sun Pharmaceutical Industries | ₹ 1,743.00 | ₹ 4,18,194 Cr. | 38.4x | 5.6x | 14.2% | 19.1% |
| Divi's Laboratories | ₹ 8,984.00 | ₹ 2,38,497 Cr. | 73.3x | 11.5x | 16.2% | 24.3% |
| Torrent Pharmaceuticals | ₹ 4,482.00 | ₹ 1,70,475 Cr. | 72.7x | 19.2x | 27.1% | 15.3% |
| Cipla | ₹ 1,337.00 | ₹ 1,08,011 Cr. | 27.6x | 3.3x | 11.8% | 13.7% |
| Zydus Lifesciences | ₹ 1,127.85 | ₹ 1,12,503 Cr. | 21.2x | 4.2x | 19.7% | 18.5% |
Prices are delayed and for information only. Nothing on this page is investment advice.